Premium
Increased expression of HB‐EGF and its receptor erbB4/HER4 in accelerated anti‐GBM disease
Author(s) -
LEVIDIOTIS Vicki,
KHONG Tee Fern,
KATERELOS Marina,
FRASER Scott,
POWER David Anthony
Publication year - 2002
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1046/j.1440-1797.2002.00113.x
Subject(s) - heparin binding egf like growth factor , epidermal growth factor , erbb4 , epidermal growth factor receptor , medicine , receptor , immunohistochemistry , kidney , cancer research , endocrinology , receptor tyrosine kinase
SUMMARY: In the kidney, heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) and its receptors, epidermal growth factor‐receptor (EGF‐R) and human epidermal receptor 4 (erbB4/HER4), may be important in the response of cells to tissue injury. to further define the role of HB‐EGF, we have determined its distribution in the accelerated anti‐GBM model of kidney disease. Within the glomerulus, immunohistochemical staining showed increased HB‐EGF expression in podocytes and infiltrating macrophages. This was associated with strong de novo expression of erbB4/HER4 on podocytes. These data suggest that increased expression of HB‐EGF and erbB4/HER4 is a response to inflammation in the glomerulus in accelerated anti‐GBM disease. to determine the potential role of HB‐EGF in anti‐GBM disease, a blocking monoclonal antibody against HB‐EGF (DE10) was administered by intravenous injection. There was, however, no significant difference in the extent of 24 h urinary protein, renal function, or histological appearances. the effects of blocking HB‐EGF, therefore, may be masked by the redundancy in the EGF growth factor family.